- Report
- April 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €2538EUR$2,789USD£2,156GBP
- Drug Pipelines
- March 2024
- 210 Pages
Global
From €7236EUR$7,950USD£6,146GBP
- Report
- January 2019
- 18 Pages
Global
From €9102EUR$10,000USD£7,731GBP
Campath is a type of drug used to treat leukemia, a type of cancer that affects the blood and bone marrow. It is a monoclonal antibody, meaning it is a type of protein that binds to a specific target on the surface of cancer cells. Campath works by targeting and destroying the cancer cells, while leaving healthy cells unharmed. It is used in combination with other drugs to treat acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL).
Campath is available in both intravenous and subcutaneous forms, and is typically administered in a hospital or clinic setting. It is usually given in combination with other drugs, such as chemotherapy or radiation therapy. The side effects of Campath can include nausea, vomiting, diarrhea, and fatigue.
The Campath market is highly competitive, with several companies offering their own versions of the drug. Some of the major players in the market include Genentech, Novartis, and Bristol-Myers Squibb. Other companies include Amgen, Merck, and Pfizer. Show Less Read more